Holly Gwaltney
Nurse Practitioner · Orangeburg, SCNPI 1871526335
Payments from drug & device makers
Across 152 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$262
- Abbott$232
- Novo Nordisk$186
- Novartis$181
- Esperion Therapeutics, Inc.$157
- Boehringer Ingelheim$113
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,334100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $262 |
| Abbott | 12 | $232 |
| Novo Nordisk | 9 | $186 |
| Novartis | 10 | $181 |
| Esperion Therapeutics, Inc. | 13 | $157 |
| Boehringer Ingelheim | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $112 |
| Lilly USA, LLC | 7 | $104 |
| Amgen(2 entities) | 7 | $97 |
| GSK | 7 | $85 |
| Amarin Pharma, Inc. | 5 | $84 |
| Biohaven Pharmaceuticals, Inc. | 4 | $81 |
| Johnson & Johnson | 4 | $81 |
| Sanofi-aventis U.S. LLC | 5 | $70 |
| Bayer | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Astellas Pharma US Inc | 3 | $55 |
| Pfizer | 4 | $53 |
| AstraZeneca | 4 | $48 |
| Merck | 3 | $38 |
| Eisai Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Organon | 2 | $26 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Insmed, Inc. | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $12 |
How this compares
$2,334 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $16,152 |
| Mirtazapine | 140 | $1,512 |
| Quetiapine Fumarate | 82 | $1,404 |
| Potassium Chloride | 85 | $1,231 |
| Levemir FlexpenInsulin Detemir | 25 | $1,148 |
| Memantine Hcl | 51 | $1,135 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $1,111 |
| Pantoprazole Sodium | 133 | $775 |
| Buspirone Hcl | 158 | $757 |
| Duloxetine Hcl | 17 | $751 |
| Donepezil Hcl | 57 | $714 |
| Tamsulosin Hcl | 87 | $653 |
| Gabapentin | 67 | $629 |
| Rosuvastatin Calcium | 64 | $577 |
| Trazodone Hcl | 107 | $513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $16,152106 claims |
| Lilly USA, LLCOlanzapine | $104 | $21847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Orangeburg
- Jenna DavisColumbia$202K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
- Melissa BramanteColumbia$19K
- Gail KirbyGreer$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.